[Trial use of Sophia-32].
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D004412:Dysmenorrhea / Q000188:drug therapy; D005260:Female; D006801:Humans; D008595:Menorrhagia / Q000188:drug therapy; D008656:Mestranol / Q000008:administration & dosage / Q000627:therapeutic use*; D009640:Norethindrone / Q000008:administration & dosage / Q000627:therapeutic use*; D010049:Ovarian Diseases / Q000188:drug therapy; D010060:Ovulation / Q000187:drug effects; D011276:Pregnanediol / Q000652:urine; D011293:Premenstrual Syndrome / Q000188:drug therapy; D014592:Uterine Hemorrhage / Q000188:drug therapy
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D008656:Mestranol; D011276:Pregnanediol; D009640:Norethindrone